Which has grown faster, HIND or KPTI?

Over the past five years, KPTI grew revenue faster — HIND at a -60.54% CAGR versus KPTI at 7.47%.

How have HIND and KPTI total returns compared?

Over the past 5 years, HIND delivered -92.93% and KPTI delivered -62.18% annualized total return. Past performance doesn't predict future results.

Vyome Holdings, Inc. (HIND) vs Karyopharm Therapeutics Inc. (KPTI)

A side-by-side comparison of Vyome Holdings, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HIND

Vyome Holdings, Inc.

$14M

$1.99HealthcareDelayed quote: Oct 6, 2026, 11:32 AM EDT

KPTI

Karyopharm Therapeutics Inc.

$15M

$0.67HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

Total return — HIND vs KPTI

growth of $100 · dividends reinvested · last 10y

HIND -100.0% (-84.2%/yr)KPTI -99.5% (-41.7%/yr)KPTI compounded faster over this window

Log scale — wide-divergence pair

HIND KPTI

HIND vs KPTI: by the numbers

•KPTI is the larger company ($15M vs $14M market cap).
•Both run net losses; KPTI's is the smaller (-153.28% vs -8716.77% net margin).
•KPTI grew revenue faster over the past five years (7.47% vs -60.54% CAGR).

Metrics side by side

Valuation

Metric	HIND	KPTI
P/S ratio	107.67	0.10
P/B ratio	2.31	N/A
FCF yield	3.76%	N/A

Profitability

Metric	HIND	KPTI
Gross margin	64.68%	95.88%
Operating margin	-859.22%	-56.17%
Net margin	-8716.77%	-153.28%
ROE	-186.95%	N/A
ROIC	-57.53%	N/A

Growth (annualized)

Metric	HIND	KPTI
Revenue CAGR (5Y)	-60.54%	7.47%
Total return CAGR (5Y)	-92.93%	-62.18%

Frequently asked

Which has grown faster, HIND or KPTI?: Over the past five years, KPTI grew revenue faster — HIND at a -60.54% CAGR versus KPTI at 7.47%.
How have HIND and KPTI total returns compared?: Over the past 5 years, HIND delivered -92.93% and KPTI delivered -62.18% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HIND analysis Full KPTI analysis Interactive comparison tool

Dig into the metrics

Vyome ROE Karyopharm Therapeutics ROE Vyome operating margin Karyopharm Therapeutics operating margin Vyome revenue growth Karyopharm Therapeutics revenue growth Vyome free cash flow Karyopharm Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.